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Abstract 
Background  
Natural Killer (NK) cells have the potential to become a successful immunotherapy as 
they can target malignant cells without being direct effectors of graft-versus-host 
disease. Our group has previously shown that large numbers of functional NK cells can 
be differentiated in vitro from umbilical cord blood (CB) CD34+ cells. In order to 
produce a clinically relevant and effective therapy we hypothesise that it is dependent 
on the NK cells being able to proliferate and persist in vivo whilst still maintaining an 
optimum activation status.  
Methods 
Here, we evaluated the proliferation capacity, telomere length and terminal 
differentiation markers of NK cells differentiated in vitro. As well as identifying how 
their cytotoxicity compared against PBNK cells and CBNK cells when targeting patient 
AML blasts and solid tumor cell lines.  
Results 
We found that the differentiated NK cells could respond to interleukin-2 and proliferate 
in vitro and that telomere length was significantly increased whilst CD57 expression 
was significantly reduced in comparison to PBNK cells. The cytotoxicity of the 
differentiated NK cells was equivalent to that of the PBNK and CBNK cell controls 
and priming consistently led to higher levels of killing of patient leukemic blasts and 
solid tumour cell lines in vitro. Interestingly this activation step was not required to 
observe killing of patient AML blasts in vivo.  
Conclusions 
We are therefore able to generate NK cells from CB CD34+ cells in high numbers 
allowing for multiple infusions of highly cytotoxic NK cells that have potential to 
further proliferate in vivo. 
 
Abbreviations 
AML = acute myeloid leukemia, CB = cord blood, CBCD34+-NK cells = Natural Killer 
cells differentiated from CB CD34+ cells, CBNK cells = cord blood Natural Killer cells, 
GvHD = graft versus host, GvL = Graft versus Leukemia, HSCT = hematopoetic stem 
cell transplantation, NK = Natural Killer, NSG = NOD/SCID IL-2Rγnull, PBNK cells 
= peripheral blood Natural Killer 
  
Introduction 
Natural Killer (NK) cells are lymphocytes of the innate immune capable of cytotoxicity 
without prior sensitization. They are defined by the surface expression of CD56 and 
absence of CD3. NK cells have been shown to be effectors of Graft versus Leukemia 
(GvL) without causing graft versus host (GvHD) following hematopoetic stem cell 
transplantation (HSCT)[1] but also as an immunotherapy alone[2]. NK cells can be 
isolated directly from peripheral blood (PB) or umbilical cord blood (CB) however, as 
NK cells make up only 10-15% of circulating lymphocytes in PB[3] and 15-30% in 
CB[4] the number of cells obtained can be limited and could potentially prevent the 
option for multiple infusions. The half-life of an NK cell is reported to be around 7 
days[5], therefore multiple infusions would be necessary if longer lasting therapeutic 
results are required for the patient.  
 
Our group has previously shown that large cell numbers of NK cells capable of 
secreting high levels of IFN- and able to kill leukemic cells in vitro and in vivo can be 
differentiated from frozen CBCD34+ cells[6]. Further it has also been proven that these 
cells maintain function post cryopreservation paving the way for an off the shelf cellular 
product that can be used for multiple infusions to prevent infection or treat relapse[7]. 
 
To tackle the limitations posed by obtaining low cell numbers from PB and CB 
numerous clinical trials have been performed post expansion of the isolated NK cells 
to obtain higher cell numbers [8-12]. These products have been shown to be safe and 
some efficacy observed however consistent clinical effects are yet to be seen. It can be 
hypothesized that the lack of consistent results may be the result of an NK cell product 
which is unable to proliferate once infused into a patient following long term cell 
expansion possibly leading to a senescent population. We therefore postulate that 
proliferation, persistence and activation of NK cells in vivo is fundamental for the 
development of a clinically relevant cellular product that will be able to target tumor 
cells efficiently in patients. The aims of this study are therefore to identify if 
CBCD34+NK cells can still proliferate in vitro following additional cytokine 
stimulation, assess the “age” of the differentiated NK cells, evaluate how priming and 
IL-2 stimulation compares as a method of NK cell activation and elucidate if the resting 
and activated NK cells can lyse patient AML blasts and solid tumor cell lines. 
  
Material and Methods 
HSC samples and cell lines 
CB samples were obtained from the Anthony Nolan Cord Blood Bank with prior 
written consent from pregnant mothers and ethical committee approval (Research 
Ethics Committee reference 10/H0405/27). Patient AML samples were kindly supplied 
by Professor M. Lowdell (University College London) all of which were obtained with 
written informed consent for research into innate immunity to leukaemia. 1520, A478, 
CTV-1, HT-29, K562, MCF-7 and RAJI cell lines were cultured at 37oC/5 % CO2 with 
95% humidity in RPMI-1640 culture media (Lonza) supplemented with 10% FBS 
(Lonza) and 1% penicillin-streptomycin (Lonza). EL08.1D2 cells were cultured as 
previously described[13]. 
 
HSC differentiation into NK cells 
CB mononuclear cells were separated from whole blood by density centrifugation using 
Ficoll-PaqueTM premium (GE Healthcare). HSC were isolated using the CD34+ 
MicroBead kit (Miltenyi Biotec) as previously described[14] and frozen in FBS + 10% 
DMSO at 1 x 106 cells/mL for future use. The mean purity (%) ± SD of all isolations 
carried out was 92.43 ± 3.13 %. Thawed CD34+ cells were plated on irradiated 
EL08.1D2 cells and cultured as described by Grzywacz 2006[13] except for the 
addition of 50 ng/mL IL-15 alone for the last two weeks[6]. 
 
NK cell isolation and priming 
NK cells were isolated from PB or CB mononuclear cells using the NK Cell 
Negative Isolation Kit (Miltenyi Biotec) following the manufacturers 
recommendations. The mean purities (%) ± SD of the NK cell isolations were 92.27 
± 4.5 % for CB and 90 ± 2.2 % for PB. NK cell priming was performed using a lysate 
produced from CTV-1 cells that were kindly supplied by Professor M. Lowdell 
(University College London). NK cells and CTV-1 lysates were incubated at an NK 
cell-to-lysate ratio of 1:2 in complete media overnight. 
 
Flow Cytometry 
The following monoclonal antibodies were purchased from BD Biosciences: CD3 
(SK7), CD16 (3G8), CD56 (B159), and CD57 (NK-1). The following blocking 
antibodies were obtained from Biolegend: anti-CD16 (3G8), anti-CD178 (FasL) 
(NOK-1), anti-CD253 (TRAIL) (RIK-2), anti-CD314 (NKG2D) (MOPC-21). Surface 
staining was performed by incubation in the dark at 4 oC for 10 min with fluorochrome-
conjugated mAbs, washed and re-suspended in FACS buffer. DAPI (Life 
Technologies) was added to each sample at a concentration of 1/200 prior to 
acquisition. Cells were blocked by incubation for 30 minutes at RT with optimised 
blocking antibody concentration, alongside isotype control. The LSR Fortessa (Becton 
Dickinson) cell analyser was used to acquire data. FlowJo software (Tree Star) was 
used for data analysis. 
 
Cytotoxicity assays 
Target cells were labelled with PKH26 Red Fluorescent Cell Linker Kit (Sigma 
Aldrich) as per manufacturers instructions. Target and effector cells were seeded in 
FACS tubes at a target-to-effector ratio of 1:5 in triplicate and incubated for 4 h. 
Samples were labelled with the viability dye TO-PRO-3 iodide (Invitrogen) and 
analysed by flow cytometry.  
 
Proliferation assay 
NK cells were labeled with 2 μmol/L carboxyfluorescein succinimidyl ester (CFSE) 
per 1 × 106 cells (Invitrogen). CBCD34+ and PBNK cells were then stimulated with 
200 IU IL-2 (Prospec) and CBNK cells were stimulated with 1000 IU IL-2. 
Comparatively cells were also stimulated with 20 ng/mL IL-15 (Prospec) or primed 
with CTV-1 lysate. Proliferation was assessed on days 2, 5 and 7 post stimulation by 
flow cytometry. 
 
Telomere Length Analysis 
Telomere length analysis was performed in line with manufacturers instructions using 
the Telomere PNA kit/FITC (Dako). Denatured samples and control cells were 
incubated with a fluorescein-conjugated peptide nucleic acid (PNA) probe. After 
incubation with a DNA staining solution cells were analysed by flow cytometry. 
Telomere length is then calculated relative to the 1301 internal control cells. 
 
In vivo Experiments 
NOD/SCID IL-2Rγnull (NSG) mice (8-10 weeks old) were irradiated at 3.75 Gy and 
injected intravenously with 1×106 PKH26 labelled patient AML blasts followed by 
20×106 resting or primed CBCD34+-NK cells 24 h later. Control mice were injected 
with PKH26 labelled AML cells only. All mice were culled 48 h post injection of 
PKH26 labelled AML cells and then the presence of the PKH26 labelled AML cells 
and NK cells was assessed in different tissues. All experiments were performed in 
agreement with Home Office regulations (project license 80/1293). 
 
Statistics 
All statistical analysis was carried out using GraphPad Prism (GraphPad Software, La 
Jolla, CA) using the non-parametric Mann-Whitney test. Results are presented as 
median ± range, p values < 0.05 were considered statistically significant. 
  
Results 
CBCD34+-NK cells can still proliferate following additional cytokine stimulation 
First we analysed if NK cells differentiated in vitro from CB CD34+ cells could further 
respond to cytokine stimulation. Extensive long-term culture of NK cells has been 
associated with senescence[15] resulting in lack of response to additional cytokine 
stimulation and poor proliferation. Previously it has been shown that PBNK cells and 
CBNK cells respond to different concentrations of IL-2[16], therefore we tested the 
response of CBCD34+-NK cells to 200 IU and 1000 IU of IL-2 the optimum 
concentration for PBNK cell and CBNK cell activation respectively. Supplementary 
figure 1 shows that the cells could respond to both concentrations of IL-2 to the same 
degree. CBCD34+-NK cells can therefore be stimulated with the same concentration of 
cytokine as PBNK cells henceforth 200 IU IL-2 was used to activate NK cells 
differentiated in vitro for the rest of the study. 
 
NK cell proliferation following IL-15 stimulation was also assessed being a key 
cytokine promoting NK cell differentiation and proliferation[17]. In addition, we 
previously showed that IL-15 led to a better activation and proliferation of CBNK cells 
than IL-2 in vitro[18]. Figure 1 shows the proliferation of CBCD34+-NK cells 
following stimulation with IL-2 and IL-15 compared with PBNK cells and CBNK cells 
(Figure 1A-C). We found no difference in the proliferative response of CBCD34+-NK 
cells, PBNK cells and CBNK cells after stimulation with either IL-2 or IL-15. Taken 
together, this suggests that CBCD34+-NK cells can respond to cytokines as efficiently 
as freshly isolated PBNK cells and CBNK cells.  
  
CBCD34+-NK cells have a less exhausted phenotype over PBNK cells and CBNK 
cells 
Long-term culture of NK cells could result in exhaustion and therefore reduced anti-
tumour activity of the cellular population. Eomes and T-bet have been identified as key 
molecular markers of cellular exhaustion[19]. A comparison of their expression in 
CBCD34+-NK cells, PBNK cells and CBNK cells was carried out via RT-PCR. Figure 
2A shows no significant difference in the expression of these markers by CBCD34+-
NK cells and resting PBNK cells and CBNK cells therefore none of these cells types 
show an exhausted phenotype. As a cell matures telomere length is reduced[20], 
therefore comparing the length of CBCD34+-NK cells, PBNK cells and CBNK cells 
can give an accurate assessment of cell age. It can be seen in Figure 2B that CBCD34+-
NK cells had significantly longer telomeres than PBNK cells (p < 0.001) and although 
there is no significance this trend was also observed with CBNK cells. CBCD34+-NK 
cells therefore have a younger cell age than NK cells from other sources, this would 
imply an ability to survive and persist for longer in vivo. CD57 is expressed at the last 
stage of maturation of NK cells and has been associated with cellular exhaustion[21]. 
The expression level of this marker therefore further characterizes the life stage of the 
cells. Figure 2C shows the percentage expression of CD57 showing that PBNK cells 
had a significantly highly expression over CBCD34+-NK cells (p < 0.001) and CBNK 
cells (p < 0.001). CBNK cells also had a significantly higher CD57 expression over 
CBCD34+-NK cells (p < 0.001) further supporting that CBCD34+-NK cells show a less 
exhausted phenotype over PBNK cells and CBNK cells. 
  
Resting CBCD34+ and PBNK cells are able to target K562 cells in vitro but not 
patient AML blasts 
It is fundamental to identify if CBCD34+-NK cells are capable of demonstrating a 
cytotoxic effect against tumor cells in vitro as this is a key function required for a 
successful immunotherapy allowing for the targeting of malignancies and preventing 
relapse in patients. Cytotoxicity was assessed by a flow cytometry based method as 
primary cells are poor at up taking Cr51. Due to the absence of MHC class I on K562 
cells, they are highly susceptible to NK cell-mediated lysis and are therefore considered 
the gold standard target for assessing NK cell cytotoxic function. Resting CBCD34+-
NK cells and PBNK cells were capable of targeting the NK cell susceptible cell line 
K562 to the same degree showing that NK cells from both cell sources are fully 
functional in vitro (Figure 3A). In order to produce a successful clinical cell therapy 
NK cells must also be able to kill patient samples, cytotoxicity was therefore assessed 
against AML samples varying in severity from M1-M4. It can be seen in Figure 3B 
that there was some degree of killing observed by both CBCD34+-NK cells and PBNK 
cells however these results are inconsistent. There was no significance observed by 
either source cell so therefore further activation of NK cells is required. 
 
Priming CBCD34+ NK cells leads to enhanced cytotoxicity against K562 cells and 
successful targeting of patient AML blasts in vitro 
As a result of the lack of clinically reproducible data following cytokine activation of 
NK cells it has to be considered if there is an alternative activation method. North and 
colleagues [22, 23] have previously developed a method for stimulating NK cells based 
on a two-step activation process known as priming and triggering. A lysate has been 
shown to prime resting PBNK cells enabling significantly up regulated cytotoxicity 
against numerous targets that were previously resistant to NK cell lysis. Primed 
CBCD34+NK cells could therefore potentially produce a more robust and clinically 
effective therapy. Primed CBCD34+-NK cells showed a significantly enhanced ability 
to target K562 cells as compared to resting CBCD34+-NK cells (p < 0.001) (Figure 
4A). More importantly, Figure 4B shows that primed, as opposite to resting, 
CBCD34+-NK cells are able to consistently target patient AML blasts in vitro (p < 
0.0001) (8.067 % (0-16.49) to 45.04 % (27.02-61.15)). 
 
Priming is superior to IL-2 stimulation as a method of NK cell activation  
IL-2 is currently used routinely in numerous clinical trials to activate NK cells, 
therefore a comparison with priming was carried out against patient AML blasts, K562 
cells and the NK resistant cell line RAJI with CBCD34+-NK cells, PBNK cells and 
CBNK cells. Figure 5 shows the specific lysis of patient AML blasts, K562 cells and 
RAJI cells by resting, primed and IL-2 stimulated CBCD34+-NK cells. It can be 
observed that primed NK cells, whatever the source of NK cells considered, had a 
significantly improved cytotoxicity against AML (p< 0.001), K562 (p < 0.01) and RAJI 
cells (p < 0.01) (Figure 5A-C). When comparing the level of specific lysis by primed 
CBCD34+-NK cells, PBNK cells and CBNK cells against patient AML blasts 
(Supplementary Figure 2) it can be seen that CBCD34+-NK cells were significantly 
less cytotoxic than PBNK cells (p < 0.05) and CBNK cells (p < 0.01). This difference 
however is only 2.394 % less than PBNK cells and 7.164 % less than CBNK cells and 
is unlikely to have any improved clinical implications. It can therefore be concluded 
that priming NK cells overnight is a significantly better method of activation over IL-2 
stimulation. 
 
Priming CBCD34+-NK cells is not required to observe cytotoxicity against patient 
AML blasts in vivo 
We then analysed if primed CBCD34+-NK cells could kill patient AML blasts in vivo. 
For this irradiated NSG mice were injected with 1 x 106 PKH26 labelled AML blasts, 
followed by resting or primed CBCD34+-NK cells 24 h later. Figure 6A shows that 
PKH26 labelled AML blasts could be detected in the BM, liver, lungs and spleen 48 h 
post infusion. Interestingly, killing of patient AML blasts was observed in the liver, 
lungs and spleen of the mice injected with both resting and primed CBCD34+-NK cells 
(p < 0.01). There was no reduction in the percentage of PKH26 labelled AML cells in 
the bone marrow. Resting and primed CBCD34+-NK cells could also be detected in all 
of the organs analysed (Figure 6B). Therefore, it can be concluded that CBCD34+-NK 
cells might not require prior activation to have a cytotoxic impact on patient AML blasts 
in vivo. 
 
Cytokine stimulated CBCD34+-NK cells can proliferate significantly more than 
primed cells 
In order to identify why CBCD34+-NK cells do not require prior activation to observe 
a cytotoxic effect in vivo we compared the difference of proliferation following 
cytokine stimulation and priming. It was observed that CBCD34+-NK cells proliferated 
significantly more when activated with cytokines over priming (Supplementary 
Figure 3) (p < 0.01). This difference was not observed with PBNK cells, which could 
account for why it might not be necessary to prime CBCD34+-NK cells to achieve 
cytotoxicity in vivo.  
 
Priming leads to significantly improved cytotoxicity against solid tumor cell lines 
in vitro 
Solid tumours are notoriously difficult to target by immunotherapy so therefore it was 
assessed if resting, primed or IL-2 stimulated CBCD34+-NK cells, PBNK cells and 
CBNK cells could target solid tumor cell lines in vitro. Analysis was carried out against 
the breast adenocarcinoma MCF7 (Figure 7A), colon cancer HT29 (Figure 7B), 
melanoma 1520 (Figure 7C) and renal cell carcinoma A478 (Figure 7D). These data 
support what has been observed previously in that primed NK cells of any source were 
highly superior at targeting tumor cells over resting and cytokine stimulated NK cells 
(p < 0.01). Further it is interesting to note that resting and cytokine stimulated 
CBCD34+-NK cells were significantly more cytotoxic than PBNK cells and CBNK 
cells (p < 0.05) when targeting the colon cancer cell line HT29 (Figure 7B). 
 
CD16 is a key pathway required for NK cells to target resistant cell lines after 
priming 
To study which mechanism might be involved in targeting NK cell resistant cells a 
blocking experiment was carried out before performing an in vitro cytotoxicity assay 
against the RAJI cell line. We assessed the level of cytotoxicity after blocking of 
TRAIL and FasL, death receptors that can directly eliminate targets post 
engagement[24], the co-engagement activating receptor NKG2D and the mediator of 
antibody-dependent cellular cytotoxicity, CD16[25]. The percentage expression of 
these receptors was unchanged subsequent to priming (data not shown). After blocking 
(Figure 8A), FasL (Figure 8B) and NKG2D (Figure 8C) there was no difference 
observed in the specific lysis of RAJI cells in comparison to the unblocked controls. 
This indicates that primed CBCD34+-NK cells, PBNK cells or CBNK cells do not 
involve these receptors in the killing of NK cell resistant target cells. Blocking of CD16 
(Figure 8D) however showed significantly reduced cytotoxicity against RAJI cells 
when compared to the unblocked control of any NK source, CBCD34+ cells (p < 0.001), 
PBNK cells (p < 0.01) and CBNK cells (p < 0.001). CD16 is therefore a key pathway 
required for primed NK cells to target resistant cell lines.  
  
Discussion 
The differentiation of NK cells from CB CD34+ cells offer a rich source of highly 
functional cells that maintain function post cryopreservation allowing for the 
development of an of-the-shelf cell therapy. It is therefore necessary to further 
characterize the phenotype and function of these cells in order to elucidate how their 
biology compares to PBNK cells and CBNK cells and identify if they could be a more 
attractive source of cells for clinical immunotherapy. 
 
The capability of CB CD34+-NK cells to proliferate post infusion is key for the 
development of a successful immunotherapy however long-term culture of 
lymphocytes prior to clinical application has been associated with poor proliferation in 
vivo[15]. Here we observed that CB CD34+-NK cells could proliferate following 
additional cytokine stimulation in vitro allowing for expansion once infused into a 
patient. Further it has been identified that as normal hematopoetic cells divide in vitro 
or in vivo telomere length is reduced providing a molecular clock that triggers 
senescence [26]. Here it is shown that CB CD34+-NK cells have telomeres longer than 
PBNK cells and CBNK cells demonstrating a more youthful molecular phenotype. In 
addition the expression of the NK cell maturation marker CD57 is significantly lower 
in CB CD34+-NK cells than in PBNK cells and CBNK cells. Previous work has 
suggested that the expression of CD57 is a marker of NK cell maturation and enhanced 
cytotoxic capacity instead of an indicator of cell anergy[27]. However here we show 
that CBCD34+-NK cells have a significantly lower expression of CD57 in comparison 
to PBNK cells and CBNK cells without any variation in cytotoxic effect observed 
irrelevant of the cell source considered against a variety of different targets. It can 
therefore be hypothesized that a CD57 threshold is to be reached to demonstrate full 
NK cell maturation but as expression increases past this threshold cell senescence can 
be correlated. Finally the molecular expression of EOMES and TBET is also equivalent 
to resting PBNK and CBNK cell controls further supporting that the cells have not 
reached an exhausted phenotype and resultant impaired function that is associated with 
a limited ability to target tumor cells in mice[19] and humans[28].  
 
The cytotoxicity of the resting, primed and IL-2 stimulated cells is equal to both PBNK 
and CBNK cell controls when targeting K562 cells, patient AML blasts, RAJI cells and 
solid tumor cell lines. Demonstrating that this key function necessary to target patient 
tumors is uncompromised whether NK cells are differentiated in vitro or in vivo. Further 
blocking shows that killing by primed CBCD34+ and CBNK cells utilizes the same 
biological pathway as PBNK cells supporting previous literature[23]. 
 
Interestingly priming was not necessary to observe killing in vivo of patient AML 
blasts. This could be the result of significantly reduced proliferation by primed 
CBCD34+-NK cells in comparison to cytokine stimulation that was not observed in 
PBNK cells. Even though there is no difference observed in the IL-2 and IL-15 receptor 
expression by CBCD34+-NK cells and PBNK cells there could still be a fundamental 
difference between the cells that could result in CBCD34+-NK cells responding 
preferentially to cytokine stimulation in vivo. Further an increased expression of CD57 
has also been associated with a reduced sensitivity to cytokines[21] which could 
support previous literature that CBCD34+-NK cells can survive and persist for longer 
in vivo over other NK cell sources[6]. 
The CD34+ cells used to differentiate NK cells in vitro are collected by a non-invasive 
procedure from CB units that are not deemed suitable for transplantation. The use of 
these cells to produce NK cells for immunotherapy therefore further optimizes the use 
of clinical grade banked CB units, making the process more economically viable.  
 
Furthermore, the cells demonstrate a younger cell profile without loss of function 
implying an enhanced ability to survive and proliferate when used as a cell therapy in 
the clinic. We therefore conclude that NK cells differentiated from CB CD34+ cells are 
a more desirable source of cells for NK immunotherapy over PBNK and CBNK cells. 
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Figure Legends 
 
Figure 1: Proliferation of CBCD34+ NK cells, PBNK cells and CBNK cells post 
cytokine stimulation. Proliferation of CBCD34+-NK cells (A), PBNK cells (B) and 
CBNK cells (C) was assessed by CFSE analysis after stimulation with 200 IU of IL-2 
for CBCD34+ and PBNK cells and 1000 IU of IL-2 for CBNK cells or 20 ng/mL IL-
15. The median MFI of CFSE (± range) CBCD34+-NK cells (n=4), PBNK cells (n=4) 
and CBNK cells (n=4) is shown. 
 
Figure 2: Expression of exhaustion markers by CBCD34+ NK cells, PBNK cells 
and CBNK cells. A) Expression of EOMES and T-bet was analysed by RT-PCR. The 
median relative expression (± range) of CBCD34+-NK cells (n = 6), PBNK cells (n = 
6) and CBNK cells (n = 6) is shown. B) Telomere length analysis was carried out using 
a telomere PNA kit. Median relative telomere length (± range) of CBCD34+-NK cells 
(n = 6), PBNK cells (n = 6) and CBNK cells (n = 6) is shown. C) Percentage CD57 
expression (± range) of CBCD34+-NK cells (n = 9), PBNK cells (n = 9) and CBNK 
cells (n = 9) is shown. ** p < 0.01, *** p < 0.001. 
 
Figure 3: Killing of AML and K562 cells in vitro. In vitro killing was analysed by a 
flow cytometry based cytotoxicity assay A) Median specific K562 lysis ( range) by 
CBCD34+-NK cells (n = 8) and PBNK cells (n = 8). B) Median specific AML lysis ( 
range) by CBCD34+-NK cells (n = 18) and PBNK cells (n = 18) in vitro.  
 
Figure 4: CTV-1 lysate primes resting NK cells to lyse AML and K562 cells in 
vitro. In vitro killing was analysed by a flow cytometry based cytotoxicity assay A) 
Median specific K562 lysis ( range) by resting CBCD34+-NK cells (n = 10) and 
primed CBCD34+-NK cells (n = 10). B) Median specific AML lysis ( range) by resting 
CBCD34+-NK cells (n = 27) and primed CBCD34+-NK cells (n = 27). Statistical 
analysis was performed using Mann-Whitney test. **** p < 0.0001. 
 
Figure 5: Killing of patient AML blasts, K562 cells and RAJI cells by resting, 
primed and IL-2 stimulated CBCD34+-NK cells, PBNK cells, CBNK cells. In vitro 
killing was analysed by a flow cytometry based cytotoxicity assay. Median specific 
lysis ( range) of AML (n = 15), K562 cells (n = 5) and RAJI cells (n = 5) by CBCD34+-
NK cells (A), PBNK cells (B) and CBNK cells (C) is shown. Statistical analysis was 
performed using Mann-Whitney test * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Figure 6: Killing of AML cells in vivo by resting and primed CBCD34+-NK cells 
A) Median percentage of PKH26 labelled AML cells ( range) detected in the BM, 
liver, lungs and spleen (n = 6). B) Median percentage of NK cells ( range) detected in 
the bone marrow, liver, lungs and spleen (n = 6). Statistical analysis was performed 
using Mann-Whitney test ** p < 0.01. 
 
Figure 7: Killing of solid tumour cell lines by resting, primed and IL-2 stimulated 
CBCD34+-NK cells, PBNK cells, CBNK cells. In vitro killing was analysed by a flow 
cytometry based cytotoxicity assay. A) Median specific lysis ( range) of MCF-7 by 
resting, primed and IL-2 stimulated CBCD34+ (n = 6), PBNK (n = 6) and CBNK cells 
(n = 6). B) Median specific lysis ( range) of HT-29 by resting, primed and IL-2 
stimulated CBCD34+(n = 6), PBNK (n = 6) and CBNK cells (n = 6). C) Median specific 
lysis ( range) of 1520 by resting, primed and IL-2 stimulated CBCD34+(n = 6), PBNK 
(n = 6) and CBNK cells (n = 6). D) Median specific lysis ( range) of A478 by resting, 
primed and IL-2 stimulated CBCD34+(n = 6), PBNK (n = 6) and CBNK cells (n = 6). 
Statistical analysis was performed using Mann-Whitney test * p < 0.05 ** p < 0.01.  
 
Figure 8: Blocking of TRAIL, FasL, NKG2D and CD16 on CBCD34+, PBNK and 
CBNK cells. Receptor involvement was analysed by blocking prior to priming before 
performing an in vitro killing assay against the NK resistant cell line RAJI. A) Median 
specific lysis ( range) by resting, primed isotype, primed and primed TRAIL blocked 
CBCD34+(n = 6), PBNK (n = 6) and CBNK cells (n = 6). B) Median specific lysis ( 
range) by resting, primed isotype, primed and primed FasL blocked CBCD34+(n = 6), 
PBNK (n = 6) and CBNK cells (n = 6). C) Median specific lysis ( range) by resting, 
primed isotype, primed and primed NKG2D blocked CBCD34+(n = 6), PBNK (n = 6) 
and CBNK cells (n = 6). D) Median specific lysis ( range) by resting, primed isotype, 
primed and primed CD16 blocked CBCD34+(n = 6), PBNK (n = 6) and CBNK cells (n 
= 6). 
  
Supplementary Figure Legends 
Supplementary Figure 1: CBCD34+-NK cells can be activated by 200 IU of IL-2. 
Proliferation was assessed by CFSE analysis after stimulation with 200 (n = 3) or 1000 
IU (n = 3) of IL-2. Median MFI CFSE ( range) at D2, 5 and 7 post activation by 
CBCD34+-NK cells is shown. 
 
Supplementary Figure 2: Comparing the cytotoxicity of CBCD34+, PBNK and 
CBNK cells against patient AML blasts. In vitro killing was analysed by a flow 
cytometry based cytotoxicity assay. Median specific lysis ( range) by CBCD34+(n = 
15), PBNK (n = 15) and CBNK cells (n = 15) is shown. Statistical analysis was 
performed using Mann-Whitney test * p < 0.05. 
 
Supplementary Figure 3: Cytokine stimulated CBCD34+-NK cells are able to 
proliferate significantly more than primed CBCD34+-NK cells. Proliferation was 
assessed by CFSE analysis after stimulation with 200 IU IL-2, 20 ng/mL IL-15 or 
priming with CTV-1 lysate. A) Median MFI CFSE ( range) at D2, 5 and 7 post 
activation of CBCD34+-NK cells (n = 4) is shown. B) Median MFI CFSE ( range) at 
D2, 5 and 7 post activation of PBNK cells (n = 4) is shown. Statistical analysis was 
performed using Mann-Whitney test * p < 0.05. 
 
